林郑:合资格未有盈利生物科技公司料一个月後可纳入互联互通
行政长官林郑月娥出席行会前见记者,她指出《施政报告》中针对将未有盈利的生物科技公司纳入互联互通范围有进展,在11月27日港交所(00388.HK)已发公告,并与上交所及深交所达成协议,估计合资格公司一个月後可纳入股票标的范围,并透过沪深港通进行交易。
至於施政报告中针对港资医疗诊所在大湾区可用香港注册的药品及仪器的措施方面,中央最近公布了相关文件方案,她将安排试点单位港大深圳医院向广东省提出申请,希望获尽快审批令项目可在试点单位落实。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.